Evidence map›Paper›PMID 28636325›Full record

ArticleACS infectious diseases2017

Challenges and Hallmarks of Establishing Alkylacetylphosphonates as Probes of Bacterial 1-Deoxy-d-xylulose 5-Phosphate Synthase.

Sara Sanders, Ryan J Vierling, David Bartee, Alicia A DeColli, Mackenzie J Harrison, Joseph L Aklinski, Andrew T Koppisch, Caren L Freel Meyers

Abstract read
In one paragraph

Article in ACS infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.6field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Potent Inhibition ofACS infectious diseases · 2024
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Sara SandersDepartment of Pharmacology and Molecular Sciences, The Johns Hopkins University School of Medicine , Baltimore, Maryland 21205, United States.
Ryan J VierlingDepartment of Pharmacology and Molecular Sciences, The Johns Hopkins University School of Medicine , Baltimore, Maryland 21205, United States.
David BarteeDepartment of Pharmacology and Molecular Sciences, The Johns Hopkins University School of Medicine , Baltimore, Maryland 21205, United States.
Alicia A DeColliDepartment of Pharmacology and Molecular Sciences, The Johns Hopkins University School of Medicine , Baltimore, Maryland 21205, United States.
Mackenzie J HarrisonDepartment of Chemistry, Northern Arizona University , Flagstaff, Arizona 86011, United States.
Joseph L AklinskiDepartment of Chemistry, Northern Arizona University , Flagstaff, Arizona 86011, United States.
Andrew T KoppischDepartment of Chemistry, Northern Arizona University , Flagstaff, Arizona 86011, United States.
Caren L Freel MeyersDepartment of Pharmacology and Molecular Sciences, The Johns Hopkins University School of Medicine , Baltimore, Maryland 21205, United States.ORCID 0000-0003-1458-0897
Johns Hopkins University · USNorthern Arizona University · US

Funding

BIOCHEMISTRY, CELLULAR AND MOLECULAR BIOLOGY PROGRAMT32GM007445 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI GREEN, RACHEL · 1985 to 2021
$24.1M
PHARMACOLOGY TRAINING GRANTT32GM008763 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI FREEL MEYERS, CAREN L. · 2000 to 2019
$6.1M
The Chemistry-Biology Interface Program at Johns Hopkins UniversityT32GM080189 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI ROKITA, STEVEN E · 2008 to 2022
$3.5M
Targeting Non-mammalian Isoprenoid BiosynthesisR01GM084998 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI FREEL MEYERS, CAREN L. · 2010 to 2019
$3.0M
NIGMS NIH HHS R01 GM084998NIGMS NIH HHS T32 GM007445NIGMS NIH HHS T32 GM008763NIGMS NIH HHS T32 GM080189
6 · The paper itself

Abstract

1-Deoxy-d-xylulose 5-phosphate (DXP) synthase catalyzes the thiamin diphosphate (ThDP)-dependent formation of DXP from pyruvate and d-glyceraldehyde 3-phosphate. DXP is at a metabolic branch point in bacteria, feeding into the methylerythritol phosphate pathway to indispensable isoprenoids and acting as a precursor for biosynthesis of essential cofactors in central metabolism, pyridoxal phosphate and ThDP, the latter of which is also required for DXP synthase catalysis. DXP synthase follows a unique random sequential mechanism and possesses an unusually large active site. These features have guided the design of sterically demanding alkylacetylphosphonates (alkylAPs) toward the development of selective DXP synthase inhibitors. alkylAPs studied here display selective, low μM inhibitory activity against DXP synthase. They are weak inhibitors of bacterial growth in standard nutrient rich conditions. However, bacteria are significantly sensitized to most alkylAPs in defined minimal growth medium, with minimal inhibitory concentrations (MICs) ranging from low μM to low mM and influenced by alkyl-chain length. The longest analog (C

Indexed as

Aldose-Ketose IsomerasesAnti-Bacterial AgentsBacterial ProteinsCatalytic DomainCloning, MolecularEnzyme InhibitorsEscherichia coliGene ExpressionGlyceraldehyde 3-PhosphateMicrobial Sensitivity TestsOrganophosphonatesPlasmidsPyridoxal PhosphatePyruvic AcidRecombinant ProteinsThiamine Pyrophosphate1-deoxy-D-xylulose 5-phosphate reductoisomeraseAldose-Ketose IsomerasesAnti-Bacterial AgentsBacterial Proteinsbutylacetylphosphonatedeoxyxylulose-5-phosphate synthaseEnzyme InhibitorsGlyceraldehyde 3-PhosphateOrganophosphonatesPyridoxal PhosphatePyruvic AcidRecombinant ProteinsThiamine PyrophosphateTransferases1-deoxy-d-xylulose 5-phosphate synthasebacterial metabolic branch pointgrowth medium effectisoprenoid biosynthesisPLP biosynthesisthiamin biosynthesis

Identifiers

PMID28636325
PMCPMC5650741
OpenAlexW2638621455

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.